said<\/a> the deal will benefit about 9 million patients currently taking AstraZeneca products. It will apply to a range of the company\u2019s medications, including those used to treat asthma, chronic obstructive pulmonary disease (COPD), cardiovascular conditions, and cancer.<\/p>\nThe agreement also includes a commitment from AstraZeneca to invest $50 billion in U.S. manufacturing and research and development by 2030. According to a White House fact sheet, the company will build a new pharmaceutical production facility in Charlottesville, Va., which is expected to create 3,600 jobs.<\/p>\n
The new site will manufacture active pharmaceutical ingredients used in the company\u2019s respiratory and oncology products.<\/p>\n
The administration said the most significant price reductions will be seen in certain respiratory medicines. For example, the COPD treatment BEVESPI AEROSPHERE will reportedly be discounted by an average of 654 percent, while AIRSUPRA, an inhaler for asthma, will see a 96 percent price reduction for direct buyers. The company will also extend discounts to consumers who purchase drugs directly through a federal platform currently being developed by the Department of Health and Human Services.<\/p>\n
Friday\u2019s announcement comes just 10 days after Trump revealed a similar MFN agreement with Pfizer, which agreed to provide Medicaid with lower drug prices and participate in the new \u201cTrumpRx\u201d online platform.<\/p>\n
That site will allow patients to buy medications directly from manufacturers at substantial discounts compared with retail pharmacy prices. Pfizer said at the time that many of its products, including vaccines, blood thinners, and cancer treatments, would be available at an average discount of 50 percent through the program.<\/p>\n
The \u201cmost-favored-nation\u201d pricing initiative is part of Trump\u2019s broader effort to reduce the gap between U.S. and foreign prescription drug prices. The administration argues that American consumers have been subsidizing lower costs abroad because foreign governments use price controls and centralized purchasing to negotiate cheaper rates, while U.S. law restricts similar negotiations for federal programs like Medicare.<\/p>\n
According to data cited by the White House, Americans pay more than three times as much as residents of other high-income countries for the same brand-name medications, even after accounting for rebates and insurance discounts. Officials said the new pricing model is intended to prevent pharmaceutical companies from charging higher prices domestically while offering lower prices internationally.<\/p>\n
In addition to lowering drug costs, the administration said the AstraZeneca agreement will strengthen domestic supply chains and reduce reliance on overseas production. The White House said the Virginia facility would serve as a \u201cstrategic hub\u201d for the production of advanced pharmaceutical ingredients used in chronic disease treatments.<\/p>\n
The president framed the announcement as part of his ongoing effort to ensure that American patients \u201cget the best deal anywhere in the world\u201d on prescription drugs.<\/p>\n
\u201cThis agreement will bring immediate relief to millions of Americans struggling with the cost of their medications,\u201d Trump said. \u201cIt\u2019s another step in putting American patients first.\u201d<\/p>\n
<\/div>\n
<\/path><\/svg><\/i> <\/div>\n","protected":false},"excerpt":{"rendered":"
President Donald Trump on Friday announced a new agreement with a major pharmaceutical manufacturer that will tie the company\u2019s U.S. drug prices to the lowest rates offered in other developed countries, expanding the administration\u2019s \u201cmost-favored-nation\u201d policy for prescription drug costs. The deal, unveiled during an Oval Office event with AstraZeneca Chief Executive Officer Pascal Soriot,…<\/p>\n
Read More “Trump Announces Major Drug Pricing Agreement Aimed At Lowering Costs”<\/span> »<\/a><\/p>\n<\/div>\n
<\/path><\/svg><\/i> <\/div>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-16361","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/readmore.cx\/index.php?rest_route=\/wp\/v2\/posts\/16361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/readmore.cx\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/readmore.cx\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/readmore.cx\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/readmore.cx\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16361"}],"version-history":[{"count":1,"href":"https:\/\/readmore.cx\/index.php?rest_route=\/wp\/v2\/posts\/16361\/revisions"}],"predecessor-version":[{"id":16362,"href":"https:\/\/readmore.cx\/index.php?rest_route=\/wp\/v2\/posts\/16361\/revisions\/16362"}],"wp:attachment":[{"href":"https:\/\/readmore.cx\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/readmore.cx\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/readmore.cx\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}